<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971825</url>
  </required_header>
  <id_info>
    <org_study_id>CC-92252-CP-001</org_study_id>
    <secondary_id>U1111-1229-5867</secondary_id>
    <secondary_id>2018-001050-10</secondary_id>
    <nct_id>NCT03971825</nct_id>
  </id_info>
  <brief_title>A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis</brief_title>
  <official_title>A Phase 1, Randomized, 3-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, randomized, single-center, 3-part, study to assess the safety,
      tolerability, PK, and PD, of single and multiple doses of CC-92252 in healthy adult subjects
      and multiple doses of CC-92252 in adult subjects with psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2018</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>From enrollment until at least 28 days after completion of study treatment</time_frame>
    <description>Number of participants with adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Observed maximum serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC0-t</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Area under the serum concentration-time curve calculated from time zero to the last measured time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC0-∞</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>The area under the curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Tmax</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Time to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - t1/2z</measure>
    <time_frame>UP to 16 weeks</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - CL/F</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Apparent clearance of drug from serum after subcutaneous dosing administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - CL</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>clearance of drug from serum after IV dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Vz/F</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Apparent volume of distribution during the terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Vz</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Apparent volume of distribution during the terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug Antibody Immunogenicity Anti-drug antibody</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Evaluation of anti‑CC-92252 antibody formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Pharmacodynamic biomarkers</measure>
    <time_frame>UP to 24 weeks</time_frame>
    <description>Change in lymphocyte counts</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Administration of CC-92252 and Placebo in Healthy Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoriasis will receive CC-92252 or placebo for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of CC-92252 and Placebo in Psoriasis subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoris will receive CC-92252 or placebo for up to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-92252</intervention_name>
    <description>CC-92252</description>
    <arm_group_label>Administration of CC-92252 and Placebo in Healthy Subjects</arm_group_label>
    <arm_group_label>Administration of CC-92252 and Placebo in Psoriasis subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Administration of CC-92252 and Placebo in Healthy Subjects</arm_group_label>
    <arm_group_label>Administration of CC-92252 and Placebo in Psoriasis subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must satisfy the following criteria to be enrolled in the study:

        Part 1, Part 2, and Part 3

          1. Subject is ≥ 18 and ≤ 55 years (Part 1 and Part 2) and age is ≥ 18 and ≤ 60 years
             (Part 3) of age at the time of signing the ICF.

          2. Subject has provided informed consent prior to initiation of any study specific
             activities/procedures

          3. Subject has a body mass index (BMI) ≥ 18 and ≤ 30 kg/m2 (Part 1 and Part 2) and BMI ≥
             18 and ≤ 33 kg/m2 (Part 3), at screening.

          4. Subject has clinical laboratory safety test results that are within normal limits or
             considered not clinically significant by the Investigator.

             Applicable to Part 3 only

          5. Subject has a clinical diagnosis of stable plaque-type PsO at least 6 months prior to
             screening, defined as:

             BSA ≥ 5% (at both screening and baseline), and sPGA score ≥ 3 (at both screening and
             baseline)

          6. Must have at least two plaques, at least 3 x 3 centimeters (cm) in diameter. One
             plaque will be used for punch biopsy and the other for Target Plaque Severity Score
             (TPSS) evaluation.

          7. Must be in generally good health (except for PsO) as judged by the Investigator

          8. No prior exposure to systemic treatments or biologics for the treatment of psoriasis

        Exclusion Criteria:

        The presence of any of the following will exclude a subject from enrollment:

        Part 1, Part 2, and Part 3

          1. Subject has any significant medical condition that would prevent the subject from
             participating in the study.

             a. Part 3 only: This exclusion does not apply to plaque psoriasis

          2. History or presence of cancer

          3. Presence of pre-cancerous conditions

          4. History or presence of a systemic infection or any potentially opportunistic
             infections

          5. Subject has any condition, including the presence of laboratory abnormalities, which
             places the subject at unacceptable risk if he/she were to participate in the study

          6. Subject has any condition that confounds the ability to interpret data from the study

          7. Subject is pregnant or breastfeeding

          8. Part 1 and Part 2 only: Subject was exposed to an investigational drug (new chemical
             entity) within 30 days preceding the first dose administration, or 5 half-lives of
             that investigational drug, if known (whichever is longer)

          9. Part 1 and Part 2 only: Subject has used any prescribed systemic or topical medication
             within 30 days prior to the first dose administration.

         10. Part 1 and Part 2 only: Subject has used any non-prescribed systemic or topical
             medication within 14 days prior to the first dose administration. Exceptions may apply
             on a case-by-case basis if considered not to interfere with the study objectives as
             agreed to and documented by the Investigator and Sponsor's Medical Monitor.

         11. Subject has a history of drug abuse (as defined by the current version of the
             Diagnostic and Statistical Manual [DSM]) within 2 years before the first dose
             administration, or positive drug screening test reflecting consumption of illicit
             drugs

         12. Subject has a history of alcohol abuse (as defined by the current version of the DSM)
             within 2 years before the first dose administration, or positive alcohol screen

         13. Subject is known to have a history of hepatitis B and/or hepatitis C, or have a
             positive result to the test for human immunodeficiency virus (HIV) antibodies at
             screening Note: Subjects who received hepatitis B vaccination and who test positive
             for hepatitis B surface antibody and negative for both hepatitis B surface antigen and
             hepatitis B core antibody remain eligible for study participation

         14. Subject smokes &gt; 10 cigarettes per day, or the equivalent in other tobacco products
             (self-reported)

         15. Vaccination within 30 days prior to the first dose administration or subject has plans
             to receive a vaccination during the course of the study

         16. Subject has received immunization with a live or live attenuated vaccine within 2
             months prior to the first dose administration or is planning to receive immunization
             with a live or live attenuated vaccine for 2 months following the last dose
             administration

         17. Subject has a positive QuantiFERON®-TB Gold (or equivalent) TB test at screening or 2
             successive indeterminate QuantiFERON®-TB Gold (or equivalent) TB tests at screening

         18. Subject has a history of incompletely treated Mycobacterium tuberculosis (TB)
             infection

         19. Topical therapy within 2 weeks of randomization (including, but not limited to,
             topical corticosteroids, retinoids or vitamin D analog preparations, tacrolimus,
             pimecrolimus, or anthralin/dithranol). Use of phototherapy within 4 weeks prior to
             first dose administration.

         20. Prolonged sun exposure or use of tanning booths Applicable to Part 3 only

         21. Presence of non-plaque psoriasis

         22. Subject has psoriasis flare within 4 weeks before screening

         23. Presence of dermatological diseases other than plaque psoriasis

         24. Presence of Psoriatic Arthritis

         25. Use of topical therapy for psoriasis within 14 days of first dosing (including but not
             limited to corticosteroids, retinoids, vitamin D analog, calcineurin inhibitors,
             salicylic acid) Exceptions: low potency topical corticosteroids will be allowed as
             background therapy for treatment of psoriatic lesions of the face, axillae and groin
             in accordance with the manufacturers' suggested usage; subjects with scalp psoriasis
             will be permitted to use coal tar shampoo and/or salicylic acid scalp preparations on
             scalp lesions; Eucerin® cream (the standard emollient for this study; or equivalent)
             will also be permitted for body lesions only. Subjects must not use these treatments
             within 24 hours prior to each clinic visit.

         26. Use of systemic therapy for psoriasis within 30 days of first dose administration

         27. Use of phototherapy for psoriasis within 30 days of first dose administration

         28. Use of systemic biologic treatment within 24 weeks of first dose administration

         29. Exposure to an immunosuppressive or immunomodulatory drug within 30 days of first dose
             administration, or five half-lives of the drug (whichever is longer)

         30. Exposure to an investigational drug (new chemical entity) within 30 days preceding the
             first dose administration, or five half-lives of that investigational drug, if known
             (whichever is longer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Ramirez-Valle, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charite Research Organisation GmBH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>May 31, 2019</last_update_submitted>
  <last_update_submitted_qc>May 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Safety</keyword>
  <keyword>CC-92252</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link:
https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>See Plan Description</ipd_time_frame>
    <ipd_access_criteria>See Plan Description</ipd_access_criteria>
    <ipd_url>https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

